GlaxoSmithKline Submits BLA for Cervarix HPV Vaccine

Findings from the phase 3 KEYNOTE-A18 trial support the supplemental biologics license application for a pembrolizumab-based regimen as a treatment for patients with newly diagnosed, high-risk, locally advanced cervical cancer.

Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.

The safety profile of tisotumab vedotin-tftv among those with recurrent or metastatic cervical cancer in the phase 3 innovaTV 301 trial appears to be comparable with prior reports of the agent.

The latest episode of Oncology Peer Review On-The-Go sits down with Michael D. Randell, MD, FACOG, to discuss the latest updates to cervical cancer screening guidelines by the American Cancer Society.

Simple hysterectomy may become the new standard of care for patients with low-risk, early-stage cervical cancer, according to an expert from Université Laval in Quebec City, Canada.

Pembrolizumab plus chemotherapy with or without bevacizumab yields a survival benefit in PD-L1 positive patients with cervical cancer in the phase 3 KEYNOTE-826 trial.